CSL112: Ph IIb AEGIS-I data

CSL said the double-blind, placebo-controlled, international Phase IIb AEGIS-I trial in 1,258 acute MI patients showed that once-weekly 2 and 6 g doses of IV CSL112 for 4 weeks each met the co-primary...